Effect of the TNF-α inhibitor adalimumab in patients with recalcitrant sarcoidosis: A prospective observational study using FDG-PET

Clinical Respiratory Journal

Volumn 6, Issue 4, 2012, Pages 238-247

  Milman, Nils ^a   Graudal, Niels ^a   Loft, Annika ^a   Mortensen, Jann ^a,b   Larsen, Janni ^a   Baslund, Bo ^a  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Adalimumab; FDG PET; Sarcoidosis; TNF ; TNF inhibitors

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; AZATHIOPRINE; CALCIUM; DIPEPTIDYL CARBOXYPEPTIDASE; FLUORODEOXYGLUCOSE F 18; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLIXIMAB; METHOTREXATE; PREDNISOLONE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BONE DISEASE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ACTIVITY; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG FUNCTION TEST; LUNG SARCOIDOSIS; LYMPH NODE; LYMPHOCYTE COUNT; MALE; NOSE DISEASE; OBSERVATIONAL STUDY; OPEN STUDY; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RECALCITRANT SARCOIDOSIS; SARCOIDOSIS; SHORT FORM 36; SPLEEN DISEASE; THYROID DISEASE; TOTAL LUNG CAPACITY; VAGINA CANDIDIASIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOPSY, NEEDLE; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; INJECTIONS, SUBCUTANEOUS; LUNG DISEASES; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PREDNISOLONE; PROSPECTIVE STUDIES; RESPIRATORY FUNCTION TESTS; SARCOIDOSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84866161437     PISSN: 17526981     EISSN: 1752699X     Source Type: Journal    
DOI: 10.1111/j.1752-699X.2011.00276.x     Document Type: Article

References (44)

1. The Joint Statement of the American Thoracic Society (ATS). the European Respiratory Society (ERS) and the World Association of Sarcoidosis (WASOG). Statement on sarcoidosis. Am J Respir Crit Care Med. 1999;160: 736-55.
2. Byg K-E, Milman N, Hansen S. Sarcoidosis in Denmark 1980-1994. A registry-based incidence study comprising 5536 patients. Sarcoidosis Vasc Diffuse Lung Dis. 2003;20: 46-52.
3. Du Bois RM, Goh N, Cullinan P. Is there a role for microorganisms in the pathogenesis of sarcoidosis? J Int Med. 2001;253: 1-14.
4. Svendsen CB, Hummelshøj T, Munthe-Fog L, Milman N, Garred P, Laursen IA, Christiansen M, Krogfelt KA. Ficolins and mannose-binding lectin in Danish patients with sarcoidosis. Respir Med. 2008;102: 1237-42.
5. Milman N. From mycobacteria to sarcoidosis - is the gate still open? Respiration. 2006;73: 15-6.
6. Gupta D, Agarwal R, Aggarwal AN, Jindal SK. Molecular evidence for the role of mycobacteria in sarcoidosis: a meta-analysis. Eur Respir J. 2007;30: 508-16.
7. Milman N, Selroos O. Pulmonary sarcoidosis in the Nordic countries 1950-1982. Epidemiology and clinical picture. Sarcoidosis. 1990;7: 50-7.
8. Milman N, Selroos O. Pulmonary sarcoidosis in the Nordic countries 1950-1982. II. Course and prognosis. Sarcoidosis. 1990;7: 113-8.
9. Moller DR. Treatment of sarcoidosis - from a basic science point of view. J Intern Med. 2003;253: 31-40.
10. Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis. 2000;17: 60-6.
11. Baughman RP, Lynch JP. Difficult treatment issues in sarcoidosis. J Intern Med. 2003;253: 41-5.
12. Müller-Quernheim J, Kienast K, Held M, Pfeifer S, Costabel U. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J. 1999;14: 1117-22.
13. Antoniu SA. Targeting the TNF-alpha pathway in sarcoidosis. Expert Opin Ther Targets. 2010;14: 21-9.
14. Ziegenhagen MW, Rothe ME, Schlaak M, Müller-Quernheim J. Bronchoalveolar and serological parameters reflecting the severity of sarcoidosis. Eur Respir J. 2003;21: 407-13.
15. Fehrenbach H, Zissel G, Goldmann T, Tschernig T, Vollmer E, Pabst R, Müller-Quernheim J. Alveolar macrophages are the main source for tumour necrosis factor-α in patients with sarcoidosis. Eur Respir J. 2003;21: 421-8.
16. Ziegenhagen MW, Rothe ME, Zissel G, Müller-Quernheim J. Exaggerated TNFα release of alveolar macrophages in corticosteroid resistant sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2002;19: 185-90.
17. Keijsers RG, Verzijlbergen JF, van Diepen DM, van den Bosch JM, Grutters JC. 18F-FDG PET in sarcoidosis: an observational study in 12 patients treated with infliximab. Sarcoidosis Vasc Diffuse Lung Dis. 2008;25: 143-9.
18. Baughmann RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2001;18: 70-4.
19. Milman N, Sørensen TB. Treatment of severe sarcoidosis using TNF-alpha-inhibitor (infliximab) (article in Danish). Ugeskr Laeger. 2006;168: 484-5.
20. Milman N, Andersen CB, Baslund B, Loft A, Iversen M. Does tumour necrosis factor-α inhibitor infliximab induce histological resolution of pulmonary sarcoid granulomas? Clin Respir J. 2007;1: 106-13.
21. Baughman RP, Drent M, Kavuru M, etal. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006;174: 795-802.
22. Field S, Regan AO, Sheahan K, Collins P. Recalcitrant cutaneous sarcoidosis responding to adalimumab but not to etanercept. Clin Exp Dermatol. 2010;35: 795-6.
23. Lahmer T, Knopf A, Lanzl I, Heemann U, Thuermel K. Using TNF-alpha antagonist Adalimumab for treatment for multisystem sarcoidosis: a case study. Rheumatol Int. 2011; DOI 10.1007/s00296-011-1968-x. [Epub ahead of print].
24. Patel SR. Systemic sarcoidosis with bone marrow involvement responding to therapy with adalimumab: a case report. J Med Case Reports. 2009;3: 8573.
25. Marnane M, Lynch T, Scott J, Stack J, Kelly PJ. Steroid-unresponsive neurosarcoidosis successfully treated with adalimumab. J Neurol. 2009;256: 139-40.
26. Alavi A, Buchpiguel CA, Loessner A. Is there a role for FDG PET imaging in the management of patients with sarcoidosis? J Nucl Med. 1994;35: 1650-2.
27. Larson SM. Cancer or inflammation? A Holy Grail for nuclear medicine. J Nucl Med. 1994;35: 1653-5.
28. Milman N, Mortensen J, Sloth C. Fluorodeoxyglucose PET scan in pulmonary sarcoidosis during treatment with inhaled and oral corticosteroids. Respiration. 2003;70: 408-13.
29. Basu S, Asopa RV, Baghel NS. Early documentation of therapeutic response at 6 weeks following corticosteroid therapy in extensive sarcoidosis: promise of FDG-PET. Clin Nucl Med. 2009;34: 689-90.
30. Keijsers RG, Grutters JC, van Veizen-Blad H, van den Bosch JM, Verzijlbergen FJ. (18)F-DG PET patterns and BAL cell profiles in pulmonary sarcoidosis. Eur J Nucl Med Mol Imaging. 2010;37: 1181-8.
31. Keijsers RG, Grutters JC, Thomeer M, Du Bois RM, Van Buul MM, Lavalaye J, Van Den Bosch JM, Verzijlbergen FJ. Imaging the inflammatory activity of sarcoidosis: sensitivity and inter observer agreement of (67)Ga imaging and (18)F-FDG PET. Q J Nucl Med Mol Imaging. 2011;55: 66-71.
32. Neels HM, Sharpé SL, van Sande ME, Fonteyne GA. Single reagent microcentrifugal assay for angiotensin converting enzyme in serum. Clin Chem. 1984;30: 163-4.
33. Bjørner JB, Damsgaard MT, Watt T, Bech P, Rasmussen NK, Kristensen TS, Modvig J, Thunedborg K. Danish manual to SF-36. A questionnaire about health status. Copenhagen 1997: Lægemiddelindustriforeningen.
34. National Institute for Health and Clinical Excellence. Infliximab (review) and adalimumab for treatment of Crohn's disease. NICE technology appraisal guidance 187. 2011. Available at: http://www.nice.org.uk/guidance/TA187 (accessed 14 Dec 2011).
35. National Institute for Health and Clinical Excellence. Adalimumab, eternacept and infliximab for the treatment of rheumatoid arthritis. NICE technology appraisal guidance 130. 2007. Available at: http://www.nice.org.uk/TA130 (accessed 14 Dec 2011).
36. Baughman RP, Lower EE, Drent M. Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them. Sarcoidosis Vasc Diffuse Lung Dis. 2008;25: 76-89.
37. Milman N, Svendsen CB, Hoffmann AL. Health-related quality of life in adult survivors of childhood sarcoidosis. Respir Med. 2009;103: 913-8.
38. Elfferich MD, Nelemans PJ, Ponds RW, De Vries J, Wijnen PA, Drent M. Everyday cognitive failure in sarcoidosis: the prevalence and the effect of anti-TNF-alpha treatment. Respiration. 2010;80: 212-9.
39. Summary of Product Characteristics, European Medicines Agency. Humira, Summary of Product Characteristics. European Medicines Agency. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000481/WC500050870.pdf (accessed 14 Dec 2011).
40. Javot L, Tala S, Scala-Bertola J, Massy N, Trenque T, Baldin B, Andréjak M, Gillet P, Petitpain N. Sarcoïdosis and Anti-TNF: a Paradoxical Class Effect? Analysis of the French Pharmacovigilance System Database and Literature Review. (Article in French). Therapie. 2011;66: 149-54.
41. Dhaille F, Viseux V, Caudron A, Dadban A, Tribout C, Boumier P, Clabaut A, Lok C. Cutaneous sarcoidosis occurring during anti-TNF-alpha treatment: report of two cases. Dermatology. 2010;220: 234-7.
42. Massara A, Cavazzini L, La Corte R, Trotta F. Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new 'class effect' paradoxical phenomenon. Two case reports and literature review. Semin Arthritis Rheum. 2010;39: 313-9.
43. Metyas SK, Tadros RM, Arkfeld DG. Adalimumab-induced noncaseating granuloma in the bone marrow of a patient being treated for rheumatoid arthritis. Rheumatol Int. 2009;29: 437-9.
44. Marcella S, Welsh B, Foley P. Development of sarcoidosis during adalimumab therapy for chronic plaque psoriasis. Australas J Dermatol. 2011;52: e8-11.